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Abstract
Objective: To determine the associations between age at first postnatal corticosteroids (PNS) 
exposure and risk for severe bronchopulmonary dysplasia (BPD) and neurodevelopmental 
impairment (NDI).
Study Design: Cohort study of 951 infants born <27 weeks gestational age at NICHD Neonatal 
Research Network sites who received PNS between 8 days of life (DOL) and 36 weeks’ 
postmenstrual age was used to produce adjusted odds ratios (aOR).
Results: Compared to infants in the reference group (22–28 DOL-lowest rate), aOR for severe 
BPD was similar for children given PNS between DOL 8–49 but higher among infants treated at 
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DOL 50–63 (aOR 1.77, 95% CI 1.03–3.06), and at DOL ≥64 (aOR 3.06, 95% CI 1.44–6.48). The 
aOR for NDI did not vary significantly by age of PNS exposure.
Conclusion: For infants at high risk of BPD, initial PNS should be considered prior to 50 DOL 
for the lowest associated odds of severe BPD.
INTRODUCTION
Bronchopulmonary dysplasia (BPD) remains one of the most common and serious neonatal 
morbidities, affecting more than 50% of surviving extremely premature infants.[1] Children 
with BPD often experience significant long-term pulmonary and neurodevelopmental 
sequelae, including cerebral palsy, cognitive impairment, and deafness.[2, 3, 4, 5] Postnatal 
administration of systemic corticosteroids (PNS) facilitates extubation and reduces the risks 
of BPD and mortality.[6, 7] However, this benefit may come at the cost of increased risk of 
cerebral palsy and other motor abnormalities,[6, 8, 9, 10, 11] particularly when 
dexamethasone is used in infants at low risk for BPD. Conversely, the balance of risks and 
benefits may favor use of dexamethasone among premature infants at high risk for BPD, in 
part because BPD is itself a risk factor for poor neurodevelopment.[1, 11, 12, 13]
Ideally, timing of PNS administration should maximize pulmonary benefit without 
increasing neurodevelopmental risk. However, the “optimal” timing is unknown. Due to 
safety concern with “early” exposure, recommendations have been made to limit PNS to 
those with evolving chronic lung disease and failure to extubate after 1–2 weeks of life.[6, 
14] The average age of first exposure to PNS has drifted toward 4 weeks of life,[15, 16] 
although the safety and efficacy of this current practice is unclear. This postponement in 
PNS may delay extubation and increase cumulative days of exposure to mechanical 
ventilation, which has been associated with development of BPD and neurodevelopmental 
impairment.[17, 18, 19]
We conducted this study to characterize, in extremely preterm infants, the associations 
between the chronological age at first PNS exposure started after the first week of life and 
the risks of severe BPD and neurodevelopmental impairment (NDI) as assessed at 2 years’ 
corrected age. Our goal was to identify a chronological age for initiation of PNS that is 
associated with the lowest risks for both BPD and NDI. We hypothesized that the 
relationships between age at first PNS exposure and BPD and NDI are non-linear, and that 
highest rates of adverse outcomes would be associated with both the earliest age at exposure 
(sicker children) and with the latest age at PNS exposure (longer invasive ventilation 
exposure).
METHODS
This was a retrospective cohort study of prospectively collected data of extremely preterm 
infants (<27 weeks’ gestational age) who first received PNS with the specified indication of 
the prevention or treatment of BPD between 8 days of life and 35 6/7 weeks’ postmenstrual 
age (PMA). This time period was selected to fall after the “early” period of corticosteroid 
administration to correspond to the common practice of starting steroids after the first week 
(non-prophylactic) of life to treat evolving BPD [6, 14], but before the official diagnosis of 
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BPD could be made at 36 weeks’ PMA. Infants were compared between PNS exposed 
groups, rather than unexposed controls, to allow for comparisons based specifically on PNS 
timing for infants. Infants were born at participating Eunice Kennedy Shriver National 
Institute of Child Health and Human Development (NICHD) Neonatal Research Network 
(NRN) centers between January 1, 2006 and December 31, 2012. Infants with major 
congenital anomalies, infants who were enrolled in a randomized, placebo-controlled trial of 
hydrocortisone for BPD, and infants for whom respiratory outcomes were unknown were 
excluded (Figure 1). Data for the NRN Generic Database (GDB) were collected by trained 
research personnel and include demographic characteristics, delivery information, medical 
morbidities, detailed respiratory data at pre-specified time points, and age at first treatment 
with systemic steroids for lung disease. Neurodevelopmental outcomes were assessed with 
standardized developmental testing and neurologic examinations conducted at 18–26 
months’ corrected age (CA). The institutional review board at each study center approved 
the data collection for the GDB and follow-up studies. Signed informed consent was 
obtained from parent or guardian for all children participating in follow-up.
Outcomes
The primary outcomes of interest were severe BPD at 36 weeks’ PMA and 
neurodevelopmental impairment (NDI) at follow-up, as well as the composite outcomes of 
severe BPD or death before 36 weeks PMA, and death or NDI at 18–26 months’ CA. The 
composite outcomes were analyzed alongside BPD and NDI in survivors because mortality 
is a competing outcome in critically-ill infants such as those included in this study. The 
pulmonary outcome of severe BPD was selected due to its stronger association with NDI 
and long-term pulmonary sequela[20, 21]. Severe BPD was defined as ≥30% oxygen and/or 
positive pressure ventilation at 36 weeks PMA.[22] The NICHD NRN definition of severe 
NDI was selected for our primary developmental outcome measure due to the expected high 
levels of delay seen in extremely preterm infants with severe respiratory morbidity[4, 5]. 
NDI was defined as any of the following: Cognitive Composite score <70 or Motor 
Composite score <70 (for those born after 1/1/2010, when the motor assessment was added 
to the NRN testing battery) on the Bayley Scales of Infant and Toddler Development, Third 
Edition (Bayley-3),[23] moderate-to-severe cerebral palsy (Gross Motor Function 
Classification Scale level of ≥2),[24] visual impairment (<20/200 bilaterally), or permanent 
hearing loss (requiring bilateral amplification or cochlear implant). All children were 
evaluated using the Bayley-3 assessment. Secondary descriptive outcomes of interest were 
additional respiratory outcomes and detailed neurodevelopmental outcomes (Bayley 
subtests, neurosensory outcomes, and Brief Infant-Toddler Social Emotional Assessment 
(BITSEA)).
Analyses
To characterize associations between timing of PNS and the study outcomes, we used a 
stepwise approach to the statistical analyses. To describe the study population and identify 
important variables for inclusion in our risk-adjustment models, we first dichotomized PNS 
exposure as “early” if the medication was started on or before 28 days of life and “late” if 
started after 28 days of life. Demographic and neonatal characteristics and outcomes were 
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compared between early and late steroid initiation groups using Fisher’s exact tests for 
categorical variables and t-tests for continuous variables.
Second, to test the hypothesis that the associations between age at first PNS exposure and 
the primary study outcomes were non-linear, we performed separate analyses with age at 
first steroid exposure defined as a continuous variable and as an ordered categorical variable. 
Restricted cubic spline (RCS) plots were created to examine the relationships between age at 
PNS initiation and each of the primary study outcomes.[25, 26] Knots were set a priori at the 
10th, 50th, and 90th percentile distribution points. Tests of linearity were performed on the 
resulting spline covariates using Wald tests.
Hierarchical multivariable logistic regression was then used to assess the associations 
between chronological age at first steroid exposure, defined as a categorical variable, and the 
risks for severe BPD or NDI. The categories for chronological age were as follows: each 
week of postnatal life between week 2 and week 5, then (because of smaller sample sizes) 
each 2-week period between weeks 6–12. The approximate inflection point identified in the 
RCS plots was used as the reference category in these models.
Logistic regression models and RCS plots were both adjusted for center as a fixed effect, 
respiratory characteristics in the first week of life (days on invasive ventilation in the first 
week of life and highest percent inspired oxygen on day of life 7), and baseline 
characteristics independently associated with BPD and/or NDI (gestational age, birth 
weight, sex, treatment with antenatal steroids, small for gestational age (<10th centile birth 
weight)[27], private insurance status). Models of NDI were also adjusted for year of birth to 
account for changes in the components of the motor assessment over time. Results of the 
adjusted logistic regression models were summarized using forest plots. All statistical 
analyses were conducted using SAS 9.3 (SAS Institute, Cary, NC, USA). Forest and RCS 
plots were created using Stata 14.0 (StataCorp, College Station, TX, USA). P values <0.05 
were considered significant and no adjustments were made for multiple testing.
RESULTS
Patient Characteristics
A total of 8228 infants were born before 27 0/7 weeks of gestation during the study period, 
of whom 951 infants (11.6%) at 25 NRN centers met all study eligibility criteria (Figure 1). 
Nineteen percent (178/951) of the cohort died. Of these deaths, 49% (88/178) occurred 
before 36 weeks PMA and 51% (90/178) occurred between 36 weeks PMA and 2-year 
follow-up. Complete developmental outcome data were available for 84% (653/773) of 
survivors. The patients with complete follow up data allowing determination of NDI status 
when compared to survivors without this data, had similar levels of severe BPD, age at 
steroid initiation, and demographic characteristics, while those without NDI data had higher 
birthweight (708±132 g vs 682 ± 133g, P <0.05) and lower exposure to antenatal steroids 
(82% (97/120) vs 91%(592/653), P =0.01). The name of the steroid drug was collected after 
4/1/2011; of the infants for whom this information is known, 73% (206/281) received 
dexamethasone and 27% (75/281) received hydrocortisone. The median age at initiation of 
PNS was 31 days (IQR 21–45).
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Baseline characteristics of children who received early (≤ 28 days) versus late (>28 days) 
steroids were similar except for marginally lower birth weight, higher rate of private 
insurance, and longer duration of exposure to invasive mechanical ventilation during the first 
week of life in the early group (Table 1). Neonatal morbidities were similar in the early and 
late steroid exposure groups except for the rate of PDA ligation, which was less common in 
the early steroid group (21% vs. 29%, P <.01).
Primary Outcomes
Among the infants who survived to 36 weeks’ PMA, 59.9% (517/863) had severe BPD. The 
composite outcome of death prior to 36 weeks PMA or severe BPD occurred in 63.6% 
(605/951). NDI was diagnosed in 25.1% (164/653) of survivors assessed at 18–26 months’ 
corrected age. The composite outcome of death or NDI at 18–26 months corrected age 
occurred in 41.2% (342/831).
Figure 2 presents the RCS plots fit to the risk-adjusted probabilities for severe BPD, NDI, 
BPD or death before 36 weeks PMA, and NDI or death before 18–26 months, based on age 
at first exposure to PNS. Knots at the 10th, 50th, and 90th percentile points corresponded to 
2, 4, and 8 weeks of life, respectively. Wald tests of the resulting spline covariates showed a 
significantly nonlinear relationship between age and the probability of each outcome (P 
<0.001, each). For all study outcomes, the RCS plots demonstrate a nadir in the probability 
curve at approximately 4–5 weeks of life.
To further explore these nonlinear relationships, we performed multivariable logistic 
regression to quantify the odds of primary outcomes at multiple categories of ages at PNS 
initiation, as compared to the reference category of 4 weeks (days of life (DOL) 22–28 
days). Figure 3 depicts these adjusted odds of severe BPD, NDI, and the composites with 
mortality. Compared to the reference group of infants first treated with PNS at 4 weeks, the 
aORs for developing severe BPD among survivors to 36 weeks PMA were similar among 
those beginning PNS during weeks 2 and 3 (DOL 8–21) and beginning during weeks 5–7 
weeks (DOL 29–49) after birth. However, the aOR for severe BPD was significantly higher 
among infants treated with PNS starting in weeks 8–9 (DOL 50–63) (1.77, 95% CI 1.03– 
3.06) and after 9 weeks (DOL ≥64) (3.06, 95% CI 1.44– 6.48). Logistic analyses of the 
composite outcome of BPD or death before 36 weeks PMA demonstrated a more significant 
U-shaped pattern with a higher aOR for death or BPD in those receiving steroids both early 
during week 3 of life (DOL 15–21) (1.68, 95% CI 1.04– 2.70) and late at week 10 or later 
(DOL ≥64) (2.75, 95% CI 1.31– 5.76), as compared to those exposed during the 4th week of 
life.
The aOR of NDI at 18–26 months did not vary significantly when compared to the reference 
group, except for when PNS were initiated during week 6–7 of life (DOL 36–49) (1.89, 95% 
CI 1.02– 3.51; Figure 3). Similarly, the aOR point estimates for NDI or death before follow-
up demonstrated a U-shaped pattern, but the differences were statistically significant only 
for infants in whom PNS were started during the second week of life (DOL 8–14) (2.64, 
95% CI 1.39– 4.99).
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Secondary outcomes are provided in Table 2. As expected, high rates of respiratory 
morbidity were seen in this cohort; 89% had moderate or severe BPD. Survivors received an 
average of 7 weeks of mechanical ventilation, with 63% discharged on oxygen. In bivariate 
analyses the early group (PNS started ≤28 days) were less likely to be discharged on oxygen 
(55% versus 68%, P <.001), were less likely to have moderate (<30% oxygen requirement at 
36 weeks) or severe BPD (84% versus 92%, P <.001), and had fewer days of invasive 
ventilation and supplemental oxygen.
For neurodevelopmental outcomes in the total surviving cohort, 15% had cognitive delay, 
24% had language delay, and 19% had motor delay at 18–26 months corrected age. The rate 
of moderate or severe cerebral palsy was 8%. There were relatively low rates of blindness 
(1%) and deafness (3%).
DISCUSSION
In this large, cohort of extremely preterm infants exposed to PNS, we found a non-linear 
relationship between chronological age at first exposure to PNS and severe BPD. While the 
percentage of children with severe BPD was lowest at 22–28 days based on unadjusted rates 
and a nadir in the continuous graph was around 3–4 weeks, the adjusted odds ratios for both 
severe BPD and the composite outcome of BPD or death before 36 weeks’ PMA were 
similar when steroids were first started between 2–7 weeks of age (DOL 8–49). When 
evaluated by week of exposure, odds of severe BPD were significantly higher when PNS 
were first initiated during the eighth week of life or later (DOL ≥ 50), as compared to when 
steroids were started during the fourth week of life (DOL 21–28). While avoiding 
unnecessary steroid exposure for preterm infants is likely beneficial, there may be a limit 
around 50 days of life where the anti-inflammatory effects of PNS are less effective after 
more prolonged exposure to mechanical ventilation and hyperoxia. We did see higher rates 
of death and composites outcomes (BPD/NDI) including death with earlier PNS. Multiple 
previous RCT have shown PNS at >7 days improved survival until the first 28 days of life 
and with similar survival to discharge.[28]. The association between higher death with early 
steroids is likely not causal and is probable partially explained by survivor treatment 
selection bias, where the children who received steroids at a later day of life had by 
definition already survived to an older age. Also, based on clinical experience, patients 
selected to receive steroids in the first couple weeks of life likely had higher levels of 
medical acuity that may not have been fully accounted for by our model.
Only three published trials have randomized the timing of systemic PNS administration 
while looking at pulmonary outcomes. One large RCT trial (n=285) compared an early 
steroid arm (<72 hours) to a moderately early steroid arm (>15 days) and showed no 
difference in oxygen dependence or death at 36 weeks.[29] A second trial was a small pilot 
that compared PNS started at 7 vs 14 days and showed earlier extubation in the group that 
received steroids at 7 days but similar dependence on oxygen at 28 days and lung function at 
3 months of age.[30] A third trial compared administration of PNS at 2 weeks of age to 4 
weeks of age in 371 ventilated infants and showed no difference in ventilator dependence or 
oxygen at 36 weeks.[31] Consistent with our results, none of these three trials showed 
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significant difference in respiratory outcomes for steroid exposure started at different 
intervals during the first month of life. Our study is the first to provide respiratory outcome 
data on patients initially provided steroids after 1 month of life and find the trend toward 
increased BPD if steroids are started after 7 weeks of life.
Only one study has looked at the risk of NDI by time of exposure PNS. An observational 
cohort study by Wilson-Costello and colleagues assessed neurodevelopmental outcomes by 
postmenstrual age at steroid exposure.[32] This study of children born between 2001 and 
2004 showed a statistically significant increase in the risk for NDI with exposure to PNS at 
33 weeks’ PMA or later.[32] Unlike the current study, the Wilson-Costello study captured all 
courses of steroids, including PNS given after 36 weeks’ PMA, and therefore provides more 
specific information on the impact of later use of steroids than the current study.
In addition to providing novel information about the associations between the timing of PNS 
exposure and prognostically-important outcomes, our study also provides valuable 
information for families about the range of respiratory and developmental outcomes for 
patients that are treated with PNS during their NICU course. Even after treatment with PNS, 
prolonged mechanical ventilation was common (mean duration 7 weeks), most infants had 
moderate or severe BPD, and the average age at discharge was 45 weeks PMA. Despite 
these risk factors for poor developmental outcomes, 75% of the population did not develop 
NDI and the 8% rate of moderate-to-severe CP was similar to the 7% rate previously 
published by the NRN for the birth cohort born 2008–2011.[33] Importantly, the standard 
NRN definition of NDI that was applied in this study only captures the most severely 
affected children. Rates of Motor, Language, and Cognitive Composite Bayley-3 scores 
greater than one standard deviation below the expected population mean in this cohort were 
between 38–56% and 12.6% of children had gross motor function classification level 2 or 
higher. These results suggest that children with moderate to severe BPD should be 
monitored closely after discharge, not only for signs of profound developmental delay but 
for more subtle delays that may have critical influence on long-term functioning.
Several limitations of this observational study are worthy of consideration. While we 
adjusted all models for important baseline characteristics, including early mechanical 
ventilation, there are likely remaining unmeasured confounders associated with the timing of 
steroid initiation. While the steroid type was not available on all participants, the majority of 
the cohort received dexamethasone and as such this study offers limited guidance on the 
optimal timing of hydrocortisone. The recent RCT of hydrocortisone vs placebo for the 
prevention of BPD started at 7–14 days of life, Stop-BPD[34], showed improved survival but 
no improvement in the rate of BPD with hydrocortisone. Based on this limited data, the 
inclusion of those patients exposed to hydrocortisone likely increased the rates of BPD and 
underestimated the effectiveness of PNS. Other limitations based on the available dataset 
include: incomplete data on respiratory severity at the time of steroid initiation, absence of 
data about cumulative PNS dosing, and subsequent courses of PNS. Lack of data on 
subsequent steroid courses limits our ability to assess the possible effect of steroid exposure 
during specific stages of brain maturation and subsequent developmental outcomes. Our use 
of the more severe NRN definition of NDI also limits our ability to potentially distinguish 
more subtle differences in development. We also had NDI status for 84% of the survivors. 
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While baseline characteristics and demographics were largely similar for those with and 
without NDI status, we cannot exclude the possibility there were small differences in 
developmental outcomes. Lastly, despite the large sample size included in this study, 
samples per week of exposure were relatively small. This may have limited our power to 
detect important yet subtle changes in the odds of developing the study outcomes at specific 
time points. Nonetheless, this study reports outcomes of nearly a thousand extremely 
preterm infants who were exposed to PNS after the first week of life and provides novel 
models of the relationships between timing of PNS exposure and important short and long-
term outcomes.
Postnatal corticosteroids continue to be commonly used to treat extremely premature infants 
with respiratory failure. A critical need remains for trials to determine the optimal use of 
systemic steroids for improving long-term pulmonary and neurodevelopmental outcomes. 
Hydrocortisone, while initially promising to provide positive anti-inflammatory lung effects 
without the negative effects on brain growth[35], has not demonstrated the same efficacy to 
reduce BPD when compared retrospectively to dexamethasone and will require further 
study.[7, 34] Currently an additional large placebo-controlled trial of hydrocortisone for 
infants with established lung disease is underway by the NRN and includes the critical 
elements of follow up of developmental and respiratory outcomes at both 2 and 5 years.[36] 
This and future studies are essential to determine optimal steroid type, dose, and timing for 
both the prevention of BPD, as well as the treatment of established lung disease.
In summary, our study suggests that when extremely preterm infants are treated with 
systemic steroids for management of BPD, treatment starting between 2 and 7 weeks (DOL 
8–49) postnatal age is associated with no greater risk of neurodevelopmental delay and may 
potentially minimize the risk of severe BPD compared to later treatment of more established 
lung disease. For infants at high risk of BPD, initial postnatal steroid should be considered 
prior to 50 days of life for the lowest associated odds of severe BPD. Despite multiple risk 
factors for poor outcomes including PNS exposure, prolonged ventilation, and high rates of 
BPD, 75% of survivors in the current cohort did not have severe neurodevelopmental 
impairmant at 2-year follow-up.
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Restricted cubic spline models showing adjusted probabilities of ratios for primary outcomes 
(BPD, NDI) and primary outcome combined with death by categories based on age of first 
initiation of steroids. Dots are the adjusted probabilities of the outcome. Solid lines indicate 
the boundaries of the 7-age categories of steroid initiation and dashed line indicates 
reference group (4 weeks). Odds ratios are adjusted for private insurance status, antenatal 
steroids, gestation age, birthweight, small for gestational age, sex, days of high frequency 
and/or conventional ventilation (HFV/CV) in first week of life, fraction of inspired oxygen 
on day 7, and center as a fixed effect. Additionally, the NDI model was also adjusted for 
birth year to account for changes in the evaluation through time (changes in target age for 
follow-up window and addition of motor component).
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Unadjusted rates and adjusted odds ratios for primary outcomes (BPD, NDI) and primary 
outcome combined with death by categories based on age of first initiation of steroids. Odds 
ratios are adjusted for private insurance status, antenatal steroids, gestation age, birthweight, 
SGA, sex, days of high frequency and/or conventional ventilation in first week of life (HFV/
CV), fraction of inspired oxygen on day 7, and center as a fixed effect. Additionally, the NDI 
model was also adjusted for birth year to account for changes in the evaluation through time 
(changes in target age for follow-up window and addition of motor component).
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Table 1.
Maternal and Infant Characteristics for First Steroid Exposure- Early vs. Late
 Steroid Exposure
 All Early (≤28 d) Late (>28 d) P
 n=951 n=420 n=531  
Steroid Initiation
Median day of life (IQR) 31 (21–45) 21 (16–25) 43 (35–54) n/a
PMA (weeks), mean ± SD 29.8±2.5 27.7±1.3 31.4±2.0 <0.001
 
Infant Characteristics
Gestational age (weeks), mean ± SD 24.9±1.0 24.9±1.0 24.9±1.0 0.36
Birth weight (g), mean ± SD 679±136 669±132 687±136 0.04
Male, n (%) 525 (55.2) 217 (51.7) 308 (58.0) 0.06
Small for gestational age, n (%) 84 (8.8) 37 (8.8) 47 (8.9) >.99
Multiple birth, n (%) 222 (23.3) 97 (23.1) 125 (23.5) 0.88
 
Maternal Characteristics
Maternal antenatal steroids, n (%) 851 (90.6) 385 (91.7) 466 (87.9) 0.07
Chorioamnionitis, n (%)
1 456 (57.5) 200 (56.0) 256 (58.7) 0.47
Private insurance, n (%)
2 409 (43.4) 199 (47.6) 210 (40.0) 0.02
Race/ethnicity, n (%)
3    0.58
  African American 338 (36.2) 153 (37.0) 185 (35.6)  
  White 555 (59.4) 246 (59.4) 309 (59.4)  
  Other 41 (4.4) 15 (3.6) 26 (5.0)  
Education, n (%)    0.08
  < High school 170 (17.9) 62 (14.8) 108 (20.3)  
  High school graduate 256 (26.9) 120 (28.6) 136 (25.6)  
  College 436 (45.8) 203 (48.3) 233 (43.9)  
  Unknown 89 (9.4) 35 (8.3) 54 (10.2)  
 
Early Respiratory Characteristics
Intubated at birth, n (%) 856 (90.0) 384 (91.4) 472 (88.9) 0.23
Received surfactant, n (%) 921 (96.8) 410 (97.6) 511 (96.2) 0.26
Days on HFV during first week of life, mean ± SD 2.7±2.9 2.8±2.8 2.6±2.9 0.36
Days on CV during first week of life, mean ± SD 3.4±2.8 3.7±2.7 3.2±2.8 <0.01
Days on HFV or CV during first week of life, mean ± SD 6.2±1.8 6.5±1.3 5.9±2.0 <0.001
Invasive Ventilation for first 7 days of life, n (%) 713 (75.0) 345 (82.1) 368 (69.3) <0.001
Highest FIO2 on day of life 7, mean ± SD 0.46±0.21 0.49±0.23 0.43±0.20 <0.001
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 Steroid Exposure
 All Early (≤28 d) Late (>28 d) P
 n=951 n=420 n=531  
Neonatal Morbidities
Late onset sepsis, n (%) 392/951 (41.2) 165 (39.3) 227 (42.8) 0.29
Meningitis, n (%) 27/951 (2.8) 8 (1.9) 19 (3.6) 0.17
Grade III/IV IVH, n (%) 161/951 (16.9) 72 (17.1) 89 (16.7) 0.93
PVL, n (%) 43/951 (4.5) 19 (4.5) 24 (4.5) 1.00
PDA, n (%) 636/951 (66.9) 277 (66.0) 359 (67.6) 0.63
PDA ligation, n (%) 241/951 (25.4) 86 (20.5) 155 (29.2) <0.01
Gastrointestinal perforation, n (%) 60/951 (6.3) 20 (4.8) 40 (7.5) 0.11
Necrotizing enterocolitis, n (%) 92/951 (9.7) 42 (10.0) 50 (9.4) 0.83
Severe ROP, n (%)
4 757/884 (85.6) 320 (86.7) 437 (84.8) 0.50
Data are mean ± SD or n (%). P values are from chi-square exact tests for categorical variables, and t-tests for continuous variables, contrasting age 
groups of >28 days vs ≤28 days age for initiation of first steroids.
1.
Data missing for 17% of infants.
2.
Data missing for 1% of infants.
3.
Data missing for 2% of infants.
4.
Severe ROP= stage ≥ 3, data missing for 7% of infants.
IQR=Interquartile range, PMA=post-menstrual age, GA=gestational age, SD=standard deviation, HFV=High frequency ventilation, 
CV=conventional ventilation, FIO2= fraction of inspired oxygen, IVH=intraventricular hemorrhage, PVL=periventricular leukomalacia, 
PDA=patent ductus arteriosus, ROP= retinopathy of prematurity
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Table 2.
Outcomes with Age at First Exposure to Steroids (unadjusted)
 Steroid Exposure
 All Early (≤28 d) Late (>28 d)
P, early vs. late
 n=951 n=420 n=531
Pulmonary Outcomes at Discharge
Severe BPD, n (%) 517/863 (60.0) 206 (57.9) 311 (61.3) 0.32
Severe BPD or Death by 36 weeks’ PMA, n (%) 605/951 (63.6) 270 (64.3) 335 (63.1) 0.73
Death by 36 weeks PMA, n (%) 88/951 (9.2) 64 (15.2) 24 (4.5) <.001
3-level BPD for infants who survived to 36 weeks’ PMA, n (%)
1  <.01
 Severe 517/863 (60.0) 206 (57.9) 311 (61.3)
 Moderate 246/863 (28.5) 93 (26.1) 153 (30.2)
 No/Mild 100/863 (11.6) 57 (16.0) 43 (8.5)
Days of ventilation, mean ±SD
2, 3 51.4±23.6 47.9±23.4 53.8±23.5 <.001
Days of supplemental oxygen, mean ±SD
2, 3 102.0±22.2 99.4±22.8 103.8±21.6 <.01
Discharged on oxygen, n (%)
2, 4 476/759 (62.7) 175 (55.4) 301 (68.0) <.001
Tracheostomy, n (%)
2 16/771 (2.0) 4 (1.3) 12 (2.6) 0.21
Length of stay (days), mean ±SD
2,5 140.7±48.8 139.5±48.7 141.6±48.9 0.55
PMA at discharge (weeks), mean ±SD
2,5 45.0±6.9 44.8±6.9 45.2±6.9 0.52
 
Neurodevelopmental Outcomes at 18–26 Months Corrected Age
  NDI composite 164/653 (25.1) 64 (23.1) 100 (26.6) 0.26
  Death by follow-up 179/929 (19.3) 103 (24.8) 76 (14.8) <.001
  NDI composite or death 342/831 (41.2) 166 (43.8) 176 (38.9) 0.17
Motor
  Bayley-3 motor composite <70
6,7 97/504 (19.2) 45 (20.6) 52 (18.2) 0.82
  Bayley-3 motor composite <85
7 221/504 (43.8) 94 (42.9) 127 (44.6) 0.30
  Gross motor function ≥ level 2
6 84/669 (12.6) 32 (11.2) 52 (13.5) 0.17
  Moderate-to-severe CP
6 53/669 (7.9) 22 (7.8) 31 (8.0) 0.96
Cognitive
  Bayley-3 cognitive composite <70
6 100/659 (15.2) 40 (14.2) 60 (15.9) 0.65
  Bayley-3 cognitive composite <85 253/659 (38.4) 113 (40.2) 140 (37.0) 0.19
Language
  Bayley-3 language composite <70 157/643 (24.4) 66 (24.0) 91 (24.7) 0.52
  Bayley-3 language composite <85 362/643 (56.3) 168 (61.1) 194 (52.7) 0.24
Sensory
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 Steroid Exposure
 All Early (≤28 d) Late (>28 d)
P, early vs. late
 n=951 n=420 n=531
  Blindness
6 7/668 (1.1) 2 (0.7) 5 (1.3) 0.54
  Deafness
6 21/670 (3.1) 7 (2.5) 14 (3.6) 0.42
Behavior
  BITSEA/problems >75%ile 194/583 (33.3) 93 (37.5) 101 (30.2) 0.08
  BITSEA/competencies <15%ile 172/567 (30.3) 81 (32.9) 91 (28.4) 0.27
Data are mean ±SD or n (%). P values are from chi-square exact tests for categorical variables, and t-tests for continuous variables, contrasting age 
groups of >28 days vs ≤28 days age for initiation of first steroids.
1.
Mild BPD=Oxygen >21% for at least 28 days but room air at 36 weeks, Moderate=<30% oxygen requirement at 36 weeks, Severe= ≥30% 
oxygen and/ or positive pressure at 36 weeks.
2.
Outcomes for survivors only.
3.
Total Days of ventilation and supplemental oxygen by status missing for <0.1% of infants.
4.
Of the 951 infants, 771 were discharged by 1 year of life. Of these, 2% were missing information.
5.
Missing for 1% of infants.
6.
Part of NDI composite.
7.
Motor score only available for kids born after 2009.
BPD=bronchopulmonary dysplasia, PMA=post-menstrual age, NDI=Neurodevelopmental Impairment, Bayley 3=Bayley Scales of Infant and 
Toddler Development, 3rd Edition, BITSEA= Brief Infant Toddler Social Emotional Assessment
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